BioSpace News Archive

BeyondSpring today announced three poster presentations of new data supporting the combination of plinabulin and G-CSF for the prevention of chemotherapy-induced neutropenia (CIN) at the European Society for Medical Oncology 2021 Congress taking place virtually September 16-21, 2021.

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has issued 2 new patents.

Rallybio today reported its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate developments.

ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference

Genapsys, Inc. today announced the additions of Priya Ray and Peter Swider to the Company’s leadership team as well as the launch of the company’s new branding and corporate website, www.genapsys.com .

InflaRx will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually.

Repligen Corporation and Navigo Proteins GmbH (“Navigo”), today announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies and Fc-fusion proteins.

KemPharm, Inc.today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Decibel Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the company’s lead gene therapy product candidate, DB-OTO, for the treatment of patients with otoferlin-related congenital hearing loss.

Crescita Therapeutics Inc. is pleased to announce that it has entered into a distribution agreement with Obagi Cosmeceuticals LLC (“Obagi”) for the exclusive rights to promote, distribute and sell the Obagi Medical ® product line in Canada.